Tang Rong Zhu, Li Zhang Zhi, Hu Dan, Kanwal Fariha, Yuan Cheng Bin, Mustaqeem Muhammad, Batool Aima Iram, Rehman Muhammad Fayyaz Ur
Department of Gastroenterology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, NO.358, Datong Road, Pudong New Area, Shanghai 200137, P. R. China.
Department of Hematology, Taihe Hospital Affiliated to the Hubei University of Medicine, Shiyan, China.
ACS Omega. 2021 Mar 9;6(11):7761-7770. doi: 10.1021/acsomega.0c05565. eCollection 2021 Mar 23.
Colorectal cancer (CRC) is one of the most common malignancies worldwide. As current therapies toward CRC, including chemotherapy and radiotherapy, pose limitations, such as multidrug resistance (MDR) as well as the intrinsic and potential cytotoxic effects, necessitating to find more effective treatment options with fewer side effects, traditional Chinese medicine (TCM) has an advantage in complementary therapies. In the present study, 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT assays), trypan blue staining, colony formation, 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) staining, cell cycle determination, and Annexin V-FITC/PI staining were used to examine the efficacy of Sanjie Yiliu Formula (SJYLF) against CRC proliferation and to investigate its underlying molecular mechanisms through protein expression of various proapoptotic factors by quantitative polymerase chain reaction (q-PCR) and Western blotting. This four-herb-TCM SJYLF can be suggested as one of the decoctions clinically effective in late-stage cancer treatment. Our results suggest that SJYLF robustly decreased the viability of only CRC cell lines (HCT-8, SW-480, HT-29, and DLD-1) and not the normal human kidney cells (HK-2). Moreover, SJYLF significantly suppressed proliferation and induced apoptosis in HCT-8 and downregulated cyclin D1, CDK4, and BCL-2, while Bax expression was upregulated at both mRNA and protein expression levels.
结直肠癌（CRC）是全球最常见的恶性肿瘤之一。由于目前针对CRC的治疗方法，包括化疗和放疗，存在局限性，如多药耐药性（MDR）以及内在和潜在的细胞毒性作用，因此需要寻找更有效的副作用更少的治疗选择，传统中药（TCM）在辅助治疗方面具有优势。在本研究中，使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐（MTT法）、台盼蓝染色、集落形成、4,6-二脒基-2-苯基吲哚二盐酸盐（DAPI）染色、细胞周期测定和膜联蛋白V-异硫氰酸荧光素/碘化丙啶染色来检测散结抑瘤方（SJYLF）对CRC增殖的疗效，并通过定量聚合酶链反应（q-PCR）和蛋白质印迹法检测各种促凋亡因子的蛋白质表达，以研究其潜在的分子机制。这种由四味中药组成的TCM方剂SJYLF可被认为是临床上对晚期癌症治疗有效的汤剂之一。我们的结果表明，SJYLF仅能显著降低CRC细胞系（HCT-8、SW-480、HT-29和DLD-1）的活力，而对正常人类肾细胞（HK-2）无影响。此外，SJYLF显著抑制HCT-8细胞的增殖并诱导其凋亡，下调细胞周期蛋白D1、细胞周期蛋白依赖性激酶4（CDK4）和B细胞淋巴瘤-2（BCL-2）的表达，而Bax在mRNA和蛋白质表达水平均上调。
